Avenue Therapeutics, Inc.
News
Avenue Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) ( Avenue or the Company ), a specialty pharmaceutical company focused on the development and commercialization...\n more…
ATXI Stock Earnings: Avenue Therapeutics Misses EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nATXI stock results show that Avenue Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Globe Newswire - Last patient visit complete in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy; topline data anticipated in second half of 2024 - Raised $4.4 million in gross proceeds...\n more…
Avenue Therapeutics, Inc. (NASDAQ:ATXI) Short Interest Update
Ticker Report Avenue Therapeutics, Inc. (NASDAQ:ATXI - Get Free Report) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 42,400 shares, a drop...\n more…
Comparing Avenue Therapeutics (NASDAQ:ATXI) and Chimerix (NASDAQ:CMRX)
Ticker Report Avenue Therapeutics (NASDAQ:ATXI - Get Free Report) and Chimerix (NASDAQ:CMRX - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two...\n more…